COVID-19 Economic Fallout May Delay Cell And Gene Therapy Reimbursement Solutions

07 Apr 2020

The economic stress on payers caused by the pandemic will cause a setback in the development of payment approaches for regenerative therapy, Blue Cross Blue Shield executive warns.

Coronavirus dollar bill — Employer-Sponsored Insurance Could Be Hampered By Pandemic's Cost

It will take longer than previously expected for payers to implement innovative approaches to managing the high cost of cell and gene therapies because of the economic burden imposed by the COVID-19 pandemic, Blue Cross Blue Shield of Massachusetts chief physician executive and senior VP for health and medical management Bruce Nash predicts.

Nash discussed the impact of the COVID-19 outbreak on payers at a Food and Drug Law Institute conference on cell...